MXPA02011531A - Beneficio de superviviencia. - Google Patents

Beneficio de superviviencia.

Info

Publication number
MXPA02011531A
MXPA02011531A MXPA02011531A MXPA02011531A MXPA02011531A MX PA02011531 A MXPA02011531 A MX PA02011531A MX PA02011531 A MXPA02011531 A MX PA02011531A MX PA02011531 A MXPA02011531 A MX PA02011531A MX PA02011531 A MXPA02011531 A MX PA02011531A
Authority
MX
Mexico
Prior art keywords
survival
water
pharmaceutical compositions
metal ion
propofol
Prior art date
Application number
MXPA02011531A
Other languages
English (en)
Spanish (es)
Inventor
David Buell Goodale
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0012599A external-priority patent/GB0012599D0/en
Priority claimed from GB0013367A external-priority patent/GB0013367D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA02011531A publication Critical patent/MXPA02011531A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA02011531A 2000-05-25 2001-05-22 Beneficio de superviviencia. MXPA02011531A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0012599A GB0012599D0 (en) 2000-05-25 2000-05-25 Survival benefit
GB0013367A GB0013367D0 (en) 2000-06-02 2000-06-02 Survival benefit
PCT/GB2001/002267 WO2001089514A2 (en) 2000-05-25 2001-05-22 Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent

Publications (1)

Publication Number Publication Date
MXPA02011531A true MXPA02011531A (es) 2003-04-25

Family

ID=26244338

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02011531A MXPA02011531A (es) 2000-05-25 2001-05-22 Beneficio de superviviencia.

Country Status (11)

Country Link
EP (1) EP1289518A2 (ko)
JP (1) JP2003534277A (ko)
KR (1) KR20030007686A (ko)
CN (1) CN1217657C (ko)
AU (1) AU2001258592A1 (ko)
BR (1) BR0111094A (ko)
CA (1) CA2408033A1 (ko)
IL (1) IL152774A0 (ko)
MX (1) MXPA02011531A (ko)
NO (1) NO20025628L (ko)
WO (1) WO2001089514A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2470500C (en) * 2001-12-28 2012-05-15 Guilford Pharmaceuticals, Inc. Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
BR0313060A (pt) 2002-07-29 2005-06-28 Transform Pharmaceuticals Inc Composições farmacêuticas aquosas de 2,6-diisopropilfenol
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition

Also Published As

Publication number Publication date
WO2001089514A2 (en) 2001-11-29
CN1430511A (zh) 2003-07-16
IL152774A0 (en) 2003-06-24
NO20025628D0 (no) 2002-11-22
CA2408033A1 (en) 2001-11-29
EP1289518A2 (en) 2003-03-12
NO20025628L (no) 2003-01-16
JP2003534277A (ja) 2003-11-18
BR0111094A (pt) 2003-04-08
AU2001258592A1 (en) 2001-12-03
KR20030007686A (ko) 2003-01-23
CN1217657C (zh) 2005-09-07
WO2001089514A3 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
DE60129134D1 (en) O/w emulsion
NZ513810A (en) Compositions and methods for improved delivery of hydrophobic therapeutic agents
BR0111196A (pt) Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
GT200100039A (es) Inhibidor de la glucogeno fosforilasa.
BR0309138A (pt) Processo para a preparação de uma composição farmacêutica finamente auto-emulsionável
BR0212163A (pt) Composição para tratamento ou prevenção de infecção em plantas
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
EA200001043A2 (ru) Соединения для лечения женской сексуальной дисфункции
BR0213040A (pt) Composto, processo para preparar um composto, e, método de tratar doenças
SV2003000633A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
HK1028879A1 (en) Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation
CA2376916A1 (en) Anaesthetic formulation comprising an nmda-antagonist and an alpha-2 adrenergic agonist
MXPA02012611A (es) Composicion anestesica, acuosa, clara.
MXPA02011531A (es) Beneficio de superviviencia.
BRPI0409413A (pt) composição farmacêutica, uso de um ácido ou sal biliar não conjugado, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um pacinete e para tratar um paciente que esteja sofrendo de uma condição ou doença tratável
MY126117A (en) Pharmaceutical compositions
BR0009214A (pt) Composições aquosas estáveis contendo umcomposto de silìcio
MY140556A (en) Clear pharmaceutical aqueous microemulsion comprising propofol and process for preparation
BR0116290A (pt) Processo para a obtenção de ácido (met) acrìlico na presença de pelo menos um estabilizador
GB2412066A (en) Method of reducing toxicity of anticancer agents
BR9908838A (pt) Uso de um glicocorticóide, processeo para tratar glomerulonefrite aguda ou crÈnica, e, composição farmacêutica para tratar glomerulonefrite
EA200801973A1 (ru) Перфторуглеродная газопереносящая эмульсия для медико-биологических целей, способ ее получения и средство для лечения (варианты)
SE0002354D0 (sv) New formulation
BR0316123A (pt) Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico
MX9708160A (es) Composicion y aparato para la limpieza de superficies.